Lindsey Parker, Shaun Mansfield, Kate Sneddon, Ben Charles and Qasim A. Rafiq
Overcoming downstream bottlenecks in cell and gene therapy manufacturing
Umbilical cord tissue and blood is banked to complement the rapidly advancing field of tissue engineering and regenerative medicine for both autologous and allogeneic therapeutic applications. Whilst many problems concerning the use of the hematopoietic and multipotential mesenchymal stromal cells contained therein may be addressed through the future development of GMP-compliant manufacturing strategies, collection and bioprocessing of these tissues can be optimised in the present to maximise clinical outcomes. In this review, we describe current procurement, processing and storage approaches for umbilical cord blood and tissue; current challenges and how these may be met to augment translation and use of therapeutics harnessing their derivatives.
Submitted for review: May 18 2017 Published: Aug 4 2017
Citation: Cell Gene Therapy Insights 2017;3(6), 489-508.